Background {#Sec1}
==========

Gastrointestinal stromal tumors (GISTs) are the most common gastrointestinal, mesenchymal neoplasm \[[@CR1]\]. Activating KIT or PDGFRA mutations represent early initiating molecular events in a majority of GISTs \[[@CR1]\]. GISTs are clinically heterogeneous, ranging from clinically benign, intermediate-risk tumors to frank sarcomas \[[@CR2], [@CR3]\]. GISTs of different risks require different clinical management strategies.

GISTs can arise from any part of the GI tract, predominantly in the stomach and small intestine and rarely in extragastrointestinal locations \[[@CR2]\]. Most GISTs occur as solitary tumors. In contrast, familial GISTs (patients with germline KIT or PDGFRA mutations) and special subtypes of GISTs (for example, neurofibromatosis type 1 (NF1)-related GISTs, sporadic succinate dehydrogenase (SDH)-deficient GISTs, and Carney triad syndrome-related GISTs) usually develop as multiple lesions \[[@CR4]--[@CR7]\]. However, GISTs originating multifocally in patients lacking evidence of familial or syndromic GISTs or SDH-deficient GISTs which were mentioned above rarely exist. Sometimes it is difficult to distinguish multiple sporadic GISTs from metastatic GISTs. The clinical management of these patients is not mentioned in current guidelines since reports of the clinicopathological features and prognostic information of multiple sporadic GISTs are still very limited \[[@CR8]--[@CR14]\].

In this study, we examined 27 patients with multiple sporadic GISTs without evidence of familial or syndromic GISTs or SDH-deficient GISTs. The clinicopathological characteristics, genetic mutation types, and prognoses were summarized. These features were compared with those of primary GISTs with a single lesion or metastatic GISTs in our center and with the case series reported in the previous literature. This study will enable us to provide evidence for the proper clinical management of multiple sporadic GISTs in the future.

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

We reviewed the preoperative imaging data, surgical records, and histopathological records of all 1660 patients diagnosed with GISTs between January 2005 and September 2019 at Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China. Follow-up information was obtained during regular outpatient visits or by telephone calls to the patients. Patient selection is shown in Fig. [1](#Fig1){ref-type="fig"}. Initially, a total of 44 patients with two or more distinct GIST lesions without definite evidence of recurrence and metastasis were included. Definite evidence of metastasis was defined as a large, high-risk main tumor lesion with three or more small satellite nodules or lesions in the liver. Three patients with multiple intestinal GISTs had a known NF1 history. One patient had a familial GIST. The KIT K642E mutation was detected in six tumor lesions and blood samples from this patient. Two patients had SDH-deficient GISTs without a history of Carney triad syndrome. These six patients had special subtypes of GISTs with their own unique clinical characteristics and were excluded from further analysis. Fig. 1Patient selection in this study

The remaining 38 patients with multiple GISTs were the subjects of this study. In 19 patients in whom all lesions were assessed as very low or low risk, the lesions were separated from each other grossly and then directly diagnosed as multiple GISTs (Table [1](#Tab1){ref-type="table"}, cases 1--19). The other 19 patients all had at least one lesion that was assessed as intermediate or high risk. Since there was some doubt as to whether this group of patients had multiple GISTs or metastatic GISTs, we performed genetic testing for each lesion. A different KIT/PDGFRA mutation pattern was detected in 8 cases, supporting an independent origin for the matched lesion. These 8 cases were diagnosed as multiple sporadic GISTs (Table [1](#Tab1){ref-type="table"}, cases 20--27). In the other 11 cases, the matched lesions carried an identical KIT/PDGFRA mutation, suggesting a clonal relationship. No KIT/PDGFRA gene mutation was detected in normal tissues around the tumors of these 11 patients, which could rule out the possibility that they were familial GISTs. We evaluated the prognosis of the 11 patients, and the lesions were reclassified as metastatic GISTs (Table [2](#Tab2){ref-type="table"}). Hence, truly multiple, sporadic, and nonspecific subtypes of GISTs occurred in 27 cases. In addition, 1066 cases of primary GISTs with a single lesion between January 2006 and December 2018 were also included as the control. This study was approved by the Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University. Table 1Clinicopathologic and molecular features of 27 patients with multiple sporadic GISTsNoAge/SexSite/size (cm)/MF/RiskHistotypeMutation statusImatinib/follow-up/months1a60/FST/0.8/≤5/VLRSpindleNANo/NED/1201bST/2/≤5/VLRSpindleNA2a71/FST/1/≤5/VLRSpindleNANo/NED/1082bST/2/≤5/VLRSpindleNA3a75/FST/0.4/≤5/VLRSpindleNANo/Died of GC/343bST/0.5/≤5/VLRSpindleNA4a54/FST/1/≤5/VLRSpindleNANo/NED/1044bST/1.2/≤5/VLRMixNA5a62/FST/1/≤5/VLRSpindleNANo/NED/1025bST/1/≤5/VLRSpindleNA6a47/FST/3.5/\< 5/LRSpindleKIT: p.V560delNo/NED/866bST/2/≤5/VLRSpindleKIT: p.V559D7a63/MST/2/≤5/VLRSpindleKIT: p.V559ANo/NED/607bST/0.5/≤5/VLRSpindleKIT: p.K642E8a65/FST/1.5/≤5/VLREpithelioidPDGFRA: p.D842VNo/NED/588bST/1/≤5/VLRSpindleKIT: p.L576P9a61/MST/3.5/≤5/LRSpindleKIT: p.W557GNo/NED/549bST/1.5/≤5/VLRSpindleWild type10a71/FST/3.5/≤5/LRSpindleKIT: p.L576PNo/NED/1210bST/0.5/≤5/VLRSpindleKIT: p.V559G11a68/FST/1/≤5/VLRSpindleKIT: p.W557_E561delNo/NED/4311bST/0.8/≤5/VLRSpindleKIT: p.V559_V560del12a70/FST/3.8/≤5/LRSpindleKIT: p.W557RNo/NED/3412bST/1/≤5/VLRSpindleKIT: p.V560D13a72/FSI/1.2/≤5/VLRSpindleKIT: p.L576PNo/Died of CC/3413bSI/0.8/≤5/VLRSpindleKIT p.D579del14a65/MST/4/≤5/LRMixNANo/NED/14814bST/1/≤5/VLRMixNA15a77/FST/5/≤5/LRMixPDGFRA: p.D842VNo/NED/1815bST/2/≤5/VLRSpindleKIT: p.N822K16a67/MST/5/≤5/LRSpindleKIT: p.V560delNo/NED/616bST/0.7/≤5/VLRSpindleKIT: p.L576P17a74/FST/4/≤5/LRSpindleKIT: p.W557_K558delNo/NED/417bST/1/≤5/VLRSpindleWild type17cST/0.3/≤5/VLRSpindleNA18a70/FST/1.8/≤5/VLRSpindleKIT: p.W557RNo/NED/1218bST/1/≤5/VLRSpindleKIT: p.D820Y18cST/0.7/≤5/VLRSpindleKIT: p.Q556_I563del19a71/MES/2.5/≤5/LRSpindleKIT: p.P577_H580dupNo/DUNC/2519bES/1.5/≤5/VLRSpindleKIT: p.W557_V559indelF20a58/FST/6/≤5/IRSpindleKIT: p.Y578_H580dupYes/NED/5220bST/8/≤5/IRSpindleKIT: p.W558_E561del21a76/FST/2.5/≤5/LRSpindleKIT: p.P577_H580dupNo/NED/3221bST/4.5/6--10/IRSpindleKIT: p.M552_W557del22a69/MST/7/≤5/IRSpindleKIT: p.W557RYes/NED/1022bST/3.5/≤5/LRSpindleKIT: p.V560E23a63/MST/6.5/≤5/IRSpindleKIT: p.P551_M552delYes/NED/4823bST/5.2/≤5/IRSpindleKIT: p.I571_D579dup24a65/MSI/6.5/≤5/HRSpindleKIT: p.G565_L576delYes/NED/824bSI/5.5/≤5/HRSpindleKIT: p.A502_Y503dup24cSI/1.2/≤5/VLRSpindleKIT: p.W557R25a70/FST/13/6--10/HRSpindleKIT: p.L576_D579dupYes/NED/525bST/1.5/≤5/VLREpithelioidPDGFRA: p.D842Y26a61/FSI/7/≤5/HRSpindleKIT: p.N566_T574delYes/NED/6226bSI/5/≤5/LRSpindleKIT: p.V560E^a^27a71/MST/2/≤5/VLRSpindleKIT: p.W557_K558delNo/NED/42^a^27bST/1/≤5/VLRSpindleKIT: p.K642E^a^27cST/6/\> 10/HRSpindleKIT:p.A502_Y503dupYes/NED/18Abbreviation: *MF*, Mitotic count per 50 high power field, *ST* Stomach, *SI* Small intestine, *ES* Esophagus, *Risk* Risk assessment according to modified NIH scheme, *VLR* Very low risk, *LR* Low risk, *IR* Intermediate risk, *HR* High risk, *NA* Not available, *NED* No evidence of disease, *DUNC* Died of unknown cause, *GC* Gastric cancer, *CC* Colon cancer^a^Case 27: The patient had metachronous GISTs. He had two GIST lesions in the stomach initially. Then, he developed another GIST in the stomach 42 months after the first surgery. We did not think it was a recurrence because the genotype of this tumor was different from that of the previous two lesionsTable 2Clinicopathologic and molecular features of 11 patients with metastatic GISTs mimicking multiple sporadic GISTsNoAge/SexSite/size (cm)/MF/RiskHistotypeMutation statusImatinib/ follow-up/months1a43/MSI/6.5/\> 10/HRSpindleKIT: p.W557_K558delYes/NED, 121bSI/3.5/\> 10/HRSpindleKIT: p.W557_K558del1cSI/1/\> 10/HRSpindleKIT: p.W557_K558del2a67/FST/14/≤5/HRSpindleKIT: p.W557_K558indelEYes/AWD/372bST/1/≤5/VLRSpindleKIT: p.W557_K558indelE3a65/MSI/11.5/≤5/HRSpindleKIT: p.A502_Y503dupYes/NED/353bSI/6.5/≤5/HRSpindleKIT: p.A502_Y503dup4a66/FST/4.5/\> 10/HRSpindleKIT: p.K558_V559delYes/DOD/684bST/3/\> 10/HRSpindleKIT: p.K558_V559del5a69/MSI/9/≤5/HRSpindleKIT: p.V559DYes/AWD/895bSI/6/≤5/HRSpindleKIT: p.V559D6a73/MST/5/\> 10/HRSpindleKIT: p.V555_V559delYes/NED/166bST/3.5/\> 10/HRSpindleKIT: p.V555_V559del7a39/FVA/2.5/\> 10/HRSpindleKIT: p. K558delYes/AWD/127bVA/2.5/\> 10/HRSpindleKIT: p. K558del8a56/FME/3.5/6--10/HRSpindleKIT: p.A502_Y503dupYes/AWD/468bME/1.5/6--10/IRSpindleKIT: p.A502_Y503dup8cME/1/6--10/IRSpindleKIT: p.A502_Y503dup9a65/MSI/11/\> 10/HRSpindleKIT: p.Y553_K558delNo/DOD/189bSI/9/\> 10/HRSpindleKIT: p.Y553_K558del10a62/MST/13/\> 10/HRSpindleKIT: p. K558_V559delYes/NED/610bST/5/\> 10/HRSpindleKIT: p. K558_V559del11a70/MST/17/\> 10/HRSpindleKIT: p.M552_V560delYes/AWD/3811bST/3/\> 10/HRSpindleKIT: p.M552_V560delAbbreviation: *MF* Mitotic count per 50 high power field, *ST* Stomach, *SI* Small intestine, *VA* Vagina; *ME* Mesentery, *Risk* Risk assessment according to modified NIH scheme, *VLR* Very low risk, *LR* Low risk, *IR* Intermediate risk, *HR* High risk, *NA* Not available, *NED* No evidence of disease, *AWD* Alive with disease, *DOD* Died of disease

Histopathological evaluation {#Sec4}
----------------------------

The histopathological diagnosis of a GIST was confirmed by two pathologists before the patients were included in the study. The largest tumor diameter and mitotic count per 50 high-power field (HPF) were evaluated as recommended by the international criteria for each tumor lesion. Risk stratification was performed according to the modified NIH scheme \[[@CR3]\].

Mutation analysis {#Sec5}
-----------------

Mutation analysis was performed with genomic DNA isolated from formalin-fixed paraffin-embedded tissues by using macrodissection and standard procedures. KIT exons 9, 11, 13, and 17 and PDGFRA exons 12 and 18 were amplified. The amplification products were purified and subjected to bidirectional Sanger sequencing by using an ABI 3130 Sequencer (Applied Biosystems, Inc., Foster City, CA).

Statistical analysis {#Sec6}
--------------------

Frequency tables were analyzed using the χ^2^ test. Disease-free survival (DFS) was defined as the time between the date of surgery and the date of relapse. Survival analysis was conducted using the Kaplan--Meier method, and survival between groups was compared by using the log-rank test. All reported *p* values were two-tailed, and statistical significance was defined as *p* \< 0.05. Analyses were performed using Statistical Package for the Social Sciences (SPSS) version 16.0 (SPSS, Inc., Chicago, IL, USA).

Results {#Sec7}
=======

Incidence of multiple sporadic GISTs {#Sec8}
------------------------------------

After excluding familial GISTs (*n* = 1), syndromic GISTs (*n* = 3, all with NF-1), SDH-deficient GISTs (*n* = 2), and metastatic GISTs that mimicked multiple GISTs (*n* = 11), 27 cases were identified as multiple sporadic GISTs, representing 1.63% of 1660 consecutive surgically resected GISTs in our hospital.

Clinicopathologic characteristics {#Sec9}
---------------------------------

The clinicopathological features of all 27 patients with multiple sporadic GISTs are summarized in Table [1](#Tab1){ref-type="table"}. There were 9 males and 18 females. The age at diagnosis ranged from 47 to 77 years (median age, 68 years). All patients had lesions located in an identical organ. Among all 58 tumors from 27 patients, the most common tumor site was the stomach (*n* = 49, 84.5%), followed by the small intestine (*n* = 7, 12.1%), and only two tumors from the same patient were located in the esophagus (3.4%). The tumor diameter ranged from 0.3 to 13 cm. Of these tumors, 35 (60.3%) were ≤ 2 cm, 13 (22.4%) were \> 2 cm and ≤ 5 cm, 9 (15.5%) were \> 5 cm and ≤ 10 cm, and only 1 tumor (1.7%) was \> 10 cm. The mitotic count per 50 high-power field (HPF) was ≤5 in 55 (94.8%) GISTs, 6--10 in 2 (3.4%) GISTs, and \> 10 in 1 GIST. Based on cell morphology, the tumors were classified as spindle (52/58, 89.7%), mixed (4/58, 6.9%), or epithelioid (2/58, 3.4%). According to the modified NIH scheme, the risk of recurrence was very low in 35 (60.3%) tumors, low in 12 (20.7%) tumors, intermediate in 6 (10.3%) tumors, and high in only 5 (8.6%) tumors. Most patients had two lesions, and only three patients had three lesions. Compared with primary GISTs with only one lesion diagnosed at our center between January 2006 and December 2018 (Table [3](#Tab3){ref-type="table"}), multiple sporadic GISTs occurred at an older age, were more common in women than in men, and were located mainly in the stomach. They were generally small in size, had a low mitotic index and were more often rated as very low risk/low risk. These differences were significant (all *p* \< 0.05). Table 3Comparison of clinicopathological features between multiple sporadic GISTs and primary GISTs with only one lesionMultiple sporadic GISTs (58 tumors from 27 patients)Primary GIST with one lesion (1066 tumors from 1066 patients)*p*Age (years)≤6014.8%, 4/2748.8%, 520/1066\< 0.001\> 6085.2%, 23/2751.2%, 546/1066SexMale33.3%, 9/2753.7%, 572/10660.037Female66.7%, 18/2746.3%, 494/1066locationStomach84.5%, 49/5860.3%, 643/1066\< 0.001Non-stomach15.5%, 9/5839.7%, 423/1066Tumor size≤2 cm60.3%, 35/5810.7%, 114/1066\< 0.0012-5 cm22.4%, 13/5842.8%, 456/10665-10 cm15.5%, 9/5834.1%, 363/1066\> 10 cm1.7%, 1/5812.5%, 133/1066Mitosis≤5/50HPF94.8%, 55/5875.7%, 807/10660.0026--10/50HPF3.4%, 2/5812.9%, 137/1066\> 10/50HPF1.7%, 1/5811.4%, 122/1066Risk assessment (modified NIH)VLR60.3%, 35/589.4%, 100/1066\< 0.001LR20.7%, 12/5838.2%, 407/1066IR10.3%, 6/5817.5%, 187/1066HR8.6%, 5/5834.9%, 372/1066Abbreviation: *HPF* high power field, *VLR* very low risk, *LR* low risk, *IR* intermediate risk, *HR*, high risk

We also compared the clinicopathologic characteristics of different tumors in the same patient. In 20 cases, the paired tumors were comparable in size; in the other seven cases, a major lesion at least three times as large as the other lesion was identified. Paired tumors displayed concordant morphology (spindle/spindle; mixed/mixed) in the majority of cases (85.2%, 23/27) and discordant morphology (spindle/mixed; spindle/epithelioid) in four cases (Fig. [2](#Fig2){ref-type="fig"}). The mitotic index of the paired lesions was concordantly low in 25 cases, whereas a different mitotic index was observed in three cases (Fig. [2](#Fig2){ref-type="fig"}). The risk assessment of the paired lesions was concordantly very low, low, intermediate and high in 10, 0, 2, and 0 cases, respectively, whereas a different risk assessment was observed in 15 cases. Fig. 2**a** A CT scan shows (red arrow) that there are two distinct GIST lesions in the stomach (case 8 in Table [1](#Tab1){ref-type="table"}). The histological features and genetic types of the two lesions were different. The tumor cells in the first tumor were epithelioid, with the PDGFRA D842V mutation, while those in the second tumor were spindle shaped, with the KIT L576P mutation. **b** A CT scan shows (red arrow) two lesions of the same GIST patient (case 21 in Table [1](#Tab1){ref-type="table"}). Although the tumor cells were spindle shaped, the cell density, atypia, mitosis and genetic types of the two lesions were different. **c** shows no difference in histological features among the three lesions from the same patient (case 24 in Table [1](#Tab1){ref-type="table"}), but the genotypes of the three lesions were not the same

Molecular findings {#Sec10}
------------------

Mutation analysis was successfully performed in a total of 45 tumors from 21 patients with multiple sporadic GISTs. KIT mutations in exons 9, 11, 13, and 17 were detected in 2, 34, 2, and 2 lesions, respectively. Three lesions had PDGFRA mutations, and two lesions were wild-type. Among all cases of multiple sporadic GISTs in our study, different mutations were detected among tumors from the same patient.

Prognostic information of patients with multiple sporadic GISTs {#Sec11}
---------------------------------------------------------------

Among 27 patients with multiple sporadic GISTs, all GIST lesions were assessed as very low or low risk in 19 patients. None of 19 patients received imatinib therapy after surgery. During a median follow-up period of 48 months (range: 4--148 months), none of 19 patients relapsed. Three patients died of other diseases, and 17 patients remained alive. The recurrence rate of multiple sporadic GISTs (all lesions were assessed as very low risk/low risk) tended to be lower than that of primary GISTs with a single lesion of the same risk diagnosed at our center (of 487 patients with single, very-low-risk and low-risk GISTs, 10 patients relapsed). However, the difference was not significant (*p* = 0.448).

Among the other eight patients with multiple sporadic GISTs (at least one lesion was assessed as intermediate risk or high risk), seven patients received imatinib therapy (three patients with an intermediate-risk tumor for 1 year and four patients with a high-risk tumor for 3 years) after surgery and only one patient who had two intermediate-risk lesions did not. They also were alive with no evidence of GIST recurrence. However, among 177 cases of intermediate-risk GIST with a single lesion in our center, 69 patients received imatinib for 1 year, and 108 patients did not; two and three patients, respectively, relapsed. Among 348 cases of high-risk GIST (most of whom received imatinib therapy for 3 or more years) with a single lesion in our center, 122 cases recurred. In the group of intermediate- or high-risk GISTs, the prognoses of patients with multiple sporadic GISTs were also not worse than those of patients with a single lesion of the same risk under the same treatment. No statistical analysis was performed because the number of patients with multiple sporadic GISTs (at least one lesion was assessed as intermediate risk or high risk) was too small.

Comparative analysis of clinicopathological characteristics and genetic types of multiple sporadic GISTs with at least one lesion assessed as intermediate or high risk and metastatic GISTs mimicking multiple sporadic GISTs {#Sec12}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In our study, it was initially difficult to determine whether 11 cases were multiple or metastatic GISTs because the genetic analysis of KIT/PDGFRA failed to show tumor multiplicity. Because of the diverse KIT and PDGFRA gene mutations in GISTs, the probability of two or more tumors from the same patient carrying the same genetic type was very small. The multiple lesions from the same patient with very-low-risk or low-risk GISTs (which were not considered metastatic GISTs) always had different KIT/PDGFRA mutation types, which also confirmed this hypothesis. In addition, the 11 patients had a very poor prognosis (all patients but one received imatinib therapy). During the follow-up period, five patients relapsed, two died of GISTs, and four remained alive without disease. Hence, we regarded these 11 cases as metastatic GISTs.

Among all 18 lesions from 7 patients in the truly multiple GIST group (at least one lesion assessed as intermediate or high risk), the tumor diameter ranged from 1 to 13 cm, with a median diameter of 5.35 cm. The mitotic index of most lesions (83.3%, 15/18) was less than 5/50 HPF. Among all 24 lesions from 11 patients in the truly metastatic GIST group, the tumor diameter ranged from 1 to 17 cm, with a median diameter of 4 cm. The mitotic count was ≤5 in 6 (25%) GISTs, 6--10 in 3 (12.5%) GISTs, and \> 10 in 15 (62.5%) GISTs (Fig. [3](#Fig3){ref-type="fig"}). Moreover, the mitotic index was always concordant in the multiple lesions from the same patients. A concordant hypermitotic phase in multiple lesions suggested that the tumor was metastatic. Fig. 3Shows that the three lesions from this GIST patient had concordance, high tumor cell density and obvious atypia. The mitotic index was more than 10/50 HPF. The three lesions had the same KIT mutation pattern. Finally, this case was considered a metastatic GIST

Discussion {#Sec13}
==========

Multiple sporadic GISTs are very rare, and previous reports have been mostly individual cases or have included only a small number of cases. In the current study, 27 cases of multiple sporadic GISTs were identified among 1660 cases of GISTs diagnosed at our center by histological features and an accurate genotype analysis. The incidence of multiple sporadic GISTs was 1.6%. To our knowledge, this is the largest report of multiple sporadic GISTs to date. It is generally believed that multiple GISTs are common in familial GISTs or syndrome-related GISTs, such as NF-1- or Carney triad syndrome-related GISTs. However, to our surprise, most of the multiple GISTs were sporadic without evidence of familial GISTs, syndromic GISTs or SDH-deficient GISTs in our series. This result was similar to that from another study conducted in China \[[@CR14]\]. Among 20 patients with multiple GISTs in Li el al.'s study, 2 patients had NF-1-related GISTs, 2 patients had Carney triad syndrome-related GISTs, and 16 patients had sporadic GISTs.

Multiple sporadic GISTs reported in our study usually occurred at an old age, were more common in females than in males and were located mainly in the stomach. They were generally small in size, had a low mitotic index and were more often rated as very low risk/low risk. These features were in accordance with the results of previous studies except for the predilection for females \[[@CR9]--[@CR14]\]. The results of the study by Kang et al. and ours showed that multiple sporadic GISTs were more common in females than in males \[[@CR10]\], while the results of the studies by Li et al., Haller et al., and Agaimy et al. showed that they were slightly more prevalent in males than in females \[[@CR9], [@CR12], [@CR14]\]. This discrepancy might be due to bias caused by the small sample size.

For the first time, we performed a stratified survival analysis of the prognosis of multiple sporadic GISTs. Both our study and previous studies have shown that patients with multiple sporadic GISTs (all lesions assessed as very low risk/low risk) had a very favorable prognosis. No patient, including the 19 patients in our study and the 28 patients in the literature, relapsed during follow-up \[[@CR9]--[@CR14]\]. For multiple sporadic GISTs with at least one lesion assessed as intermediate or high risk, none of eight patients (all patients but one received imatinib therapy after surgery) relapsed in our study. We also reviewed the prognoses of these patients in the previous literature. Of 22 multiple sporadic GIST patients with at least one lesion assessed as intermediate and high risk mentioned in the literature \[[@CR9]--[@CR14]\], 13 cases showed tumor multiplicity on KIT/PDGFRA mutation analysis, excluding them as metastatic GISTs. Among these 13 patients, four and nine patients had intermediate- and high-risk lesions, respectively. None of the patients with intermediate-risk lesions received imatinib therapy or relapsed. Of the 9 patients with high-risk lesions, three patients received imatinib therapy, and 6 patients did not, and one patient and 3 patients relapsed, respectively. In general, the prognoses of patients with multiple sporadic GISTs were not worse than those of patients with a single lesion at the same risk under the same treatment.

In our study, multiple lesions from the same patients with very-low-risk or low-risk GISTs (which were not considered metastatic GISTs) always had different KIT/PDGFRA mutation types. This result was similar to that of previous studies \[[@CR9]--[@CR14]\]. Among the 23 cases of multiple sporadic GISTs (very low or low risk) reported in the previous literature, only 3 cases had identical genotypes in different lesions from the same patient. We analyzed the details of these 3 patients. In Agaimy et al.'s study, the patient had two GIST lesions that were not very far apart but were separated by a thin capsule \[[@CR13]\]. Whether this case was a truly multiple GIST was questionable. One case of multiple sporadic GISTs with wild-type lesions for KIT/PDGFRA mutation analysis had been reported \[[@CR13]\]. (In the group of multiple sporadic GISTs with intermediate or high risk lesions, there were also three cases showed wild-type lesions). This situation did not exist in our study, which may be due to the exclusion of SDH-deficient GISTs. Patients with this particular subtype of GISTs were often wild-type for KIT/PDGFRA genes and had multiple tumors. This was a recently recognized subtype of GISTs that had not been identified in the previous literature. Only one case with a very low risk multiple sporadic GIST showed an identical KIT point mutation in Kang et al.'s study \[[@CR10]\]. Both the results of our study and those of previous reports demonstrate the fact that the probability of two or more tumors from the same patient carrying the same genetic type was very small.

For those patients with multifocal GISTs (at least one lesion evaluated as intermediate or high risk), if the KIT/PDGFRA mutation pattern of paired lesions is different, there is no doubt that they are multiple sporadic GISTs, and if the paired lesions have an accordant genotype, whether these patients have multiple sporadic GISTs or metastatic GISTs remains controversial. In the study by Gasparotto et al., three such cases were reported \[[@CR11]\]. Two patients with follow-up information received imatinib therapy, and one relapsed. The author regarded these cases as "truly metastatic GISTs". In contrast, such cases were classified as multiple sporadic GISTs in the studies by Li et al. (1 case) and Kang et al. (3 cases) \[[@CR10], [@CR14]\]. In Li et al.'s study, the patient had two high-risk GIST lesions and died of GISTs during the follow-up even with imatinib. In Kang et al.'s study, two patients had at least an intermediate-risk GIST lesion, and one patient had a high-risk GIST lesion. They did not receive imatinib and had no relapse. Similar to the studies by Gasparotto et al. and Li et al., the 11 patients with multifocal GISTs (paired lesions with the same KIT/PDGFRA mutation pattern) had a very poor prognosis in our study. Five patients relapsed, and two died of GISTs during the follow-up period. Therefore, we reclassified these patients as metastatic GIST patients. Although more comprehensive genetic testing was still needed to confirm whether they had metastatic GISTs, it was at least necessary to distinguish these lesions from truly multiple sporadic GISTs (with tumor multiplicity confirmed by a different KIT/PDGFRA mutation pattern), since their prognoses were different. Namely, when there are intermediate or high-risk lesions in multiple sporadic GISTs and their genotypes are consistent, the possibility of metastatic GISTs should be considered. In addition to the KIT/PDGFRA mutation pattern, our results also showed that histological features such as a concordant hypermitotic phase in multiple lesions could also help distinguish multiple GISTs from metastatic GISTs. Agaimy et al. reported that the involvement of the muscularis propria was a potentially reliable marker for primary GISTs \[[@CR12]\].

Conclusions {#Sec14}
===========

In summary, multiple sporadic GISTs were rare. The prognoses of patients with multiple sporadic GISTs were not worse than those of patients with a single lesion at the same risk under the same treatment. Multiple tumor lesions did not increase the risk of tumor recurrence. KIT/PDGFRA gene mutation analysis was necessary for each multifocal GIST lesion and could help us distinguish between multiple GISTs and metastatic GISTs. In addition, a concordant hypermitotic phase in multiple GIST lesions suggested that the tumor was metastatic.

AWD

:   Alive with disease

CC

:   Colonic cancer

DOD

:   Died of disease

DUNC

:   Died of unknown cause

ES

:   Esophagus

GC

:   Gastric cancer

GIST

:   Gastrointestinal stromal tumors

HPF

:   High power field

HR

:   High risk

IR

:   Intermediate risk

LR

:   Low risk

ME

:   Mesentery

MF

:   Mitotic count per 50 high power field

NA

:   Not available

NED

:   No evidence of disease

NF1

:   Neurofibromatosis type 1

SDHB

:   Succinate dehydrogenase

SI

:   Small intestine

ST

:   Stomach

VA

:   Vagina

VLR

:   Very low risk
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